Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aude Flechon

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
European Urology|November 18, 2021
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC TrialGiulia Baciarello, Remy Delva, Gwenaelle Gravis, et al.
Oncotarget|August 29, 2015
The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic valueXiaojun Jiang, Daniel Pissaloux, Christelle De La Fouchardiere, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNANobuaki Matsubara, Johann de Bono, David Olmos, et al.
Clinical Genitourinary Cancer|March 19, 2018
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted AgentsAntoine Angelergues, Eleni Efstathiou, Revekka Gyftaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer GroupDarren R Feldman, Anja Lorch, Andrew Kramar, et al.
Cancer Immunology, Immunotherapy : CII|May 24, 2026
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad studyKarim Amrane, Luca Campedel, Fabien Moinard-Butot, et al.
The Lancet. Oncology|March 7, 2015
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trialDaniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, et al.
JAMA Oncology|August 26, 2016
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail StudyEllen S de Morrée, Nicholas J Vogelzang, Daniel P Petrylak, et al.
Cancer Discovery|April 10, 2022
PD-1 Blockade in Solid Tumors with Defects in Polymerase EpsilonBenoit Rousseau, Ivan Bieche, Eric Pasmant, et al.
European Urology|January 15, 2008
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part IISusanne Krege, Jörg Beyer, Rainer Souchon, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
European Urology|November 18, 2021
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC TrialGiulia Baciarello, Remy Delva, Gwenaelle Gravis, et al.
Oncotarget|August 29, 2015
The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic valueXiaojun Jiang, Daniel Pissaloux, Christelle De La Fouchardiere, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNANobuaki Matsubara, Johann de Bono, David Olmos, et al.
Clinical Genitourinary Cancer|March 19, 2018
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted AgentsAntoine Angelergues, Eleni Efstathiou, Revekka Gyftaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer GroupDarren R Feldman, Anja Lorch, Andrew Kramar, et al.
Cancer Immunology, Immunotherapy : CII|May 24, 2026
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad studyKarim Amrane, Luca Campedel, Fabien Moinard-Butot, et al.
The Lancet. Oncology|March 7, 2015
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trialDaniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, et al.
JAMA Oncology|August 26, 2016
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail StudyEllen S de Morrée, Nicholas J Vogelzang, Daniel P Petrylak, et al.
Cancer Discovery|April 10, 2022
PD-1 Blockade in Solid Tumors with Defects in Polymerase EpsilonBenoit Rousseau, Ivan Bieche, Eric Pasmant, et al.
European Urology|January 15, 2008
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part IISusanne Krege, Jörg Beyer, Rainer Souchon, et al.
Pageof 5